Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.

Socially responsible companies are businesses that integrate social and environmental considerations into their core operations and decision-making processes.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Texas, on Wednesday published a 47-page report titled “The Case for Healthcare Freedom" as a roadmap to "Make American ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...